Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma

Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma

Abstract Background Sunitinib is a standard treatment for metastatic renal cell carcinoma (RCC). Currently, the data available on the effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular (CV) risk factors are limited, and we aimed to evaluate these aspects in patien...

Full description

Bibliographic Details
Main Authors:	Silvia Lai, Maria Ida Amabile, Sandro Mazzaferro, Anna Paola Mitterhofer, Angelo Mazzarella, Alessandro Galani, Giovanni Imbimbo, Rosario Cianci, Marzia Pasquali, Alessio Molfino, Study Group on Geriatric Nephrology of the Italian Society of Nephrology (SIN)
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	Cancer Medicine
Subjects:	cardiovascular risk endothelial dysfunction hypertension metabolism renal cell carcinoma renal function
Online Access:	https://doi.org/10.1002/cam4.2910

Similar Items

Geriatric syndromes are potential determinants of the medication adherence status in prevalent dialysis patients
by: Chia-Ter Chao, et al.
Published: (2016-06-01)

A nationwide survey of healthcare personnel’s attitude, knowledge, and interest toward renal supportive care in Taiwan
by: Hung-Bin Tsai, et al.
Published: (2017-07-01)

Functional assessment of chronic illness therapy—the fatigue scale exhibits stronger associations with clinical parameters in chronic dialysis patients compared to other fatigue-assessing instruments
by: Chia-Ter Chao, et al.
Published: (2016-03-01)

Ischemic Nephropaty: The Role of the Renal Artery Stenosis Revascularization on Renal Stem Cells
by: Rosario Cianci, et al.
Published: (2021-09-01)

Frail phenotype might herald bone health worsening among end-stage renal disease patients
by: Chia-Ter Chao, et al.
Published: (2017-07-01)

Distribution of glomerular diseases in Taiwan: preliminary report of National Renal Biopsy Registry–publication on behalf of Taiwan Society of Nephrology
by: Hsien-Fu Chiu, et al.
Published: (2018-01-01)

Frail phenotype is associated with distinct quantitative electroencephalographic findings among end-stage renal disease patients: an observational study
by: Chia-Ter Chao, et al.
Published: (2017-12-01)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
by: Haohao Lu, et al.
Published: (2023-03-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

Cardio-Renal Syndrome Type 4: The Correlation Between Cardiorenal Ultrasound Parameters
by: Silvia Lai, et al.
Published: (2016-09-01)

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
by: Romualdo Barroso-Sousa, et al.
Published: (2014-12-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

Fracture risk in chronic kidney disease: A Korean population-based cohort study
by: Young Eun Kwon, et al.
Published: (2019-06-01)

Spindle cell renal cell carcinoma diagnosed after sunitinib treatment for chromophobe renal cell carcinoma
by: Ruriko Honda‐Takinami, et al.
Published: (2020-03-01)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
by: Alexandra Karadimou, et al.
Published: (2011-08-01)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2020-12-01)

Un nuovo farmaco per l'iperfosfatemia
by: Sandro Mazzaferro, et al.
Published: (2016-08-01)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
by: H. Mohammad, et al.
Published: (2022-01-01)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
by: Akihiro Yoshimura, et al.
Published: (2020-09-01)

Key sunitinib‐related biomarkers for renal cell carcinoma
by: Yun Peng, et al.
Published: (2021-10-01)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
by: Çetin Ordu, et al.
Published: (2016-06-01)

Progress in mechanisms and treatment of sunitinib resistance in renal cell carcinoma
by: CHEN Zixuan, et al.
Published: (2024-10-01)

Early onset recall pneumonitis during targeted therapy with sunitinib
by: Yuasa Takeshi, et al.
Published: (2013-01-01)

The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro
by: Rafia S. Al-Lamki, et al.
Published: (2020-04-01)

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma
by: Jeannette C. Oosterwijk-Wakka, et al.
Published: (2025-02-01)

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
by: Yanli Wang, et al.
Published: (2023-11-01)

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
by: El-Hadaad Hend Ahmed, et al.
Published: (2015-12-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
by: Zeshen Wu, et al.
Published: (2022-10-01)

Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma
by: Qianwei Xing, et al.
Published: (2019-06-01)

Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells
by: Jun Ito, et al.
Published: (2023-08-01)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
by: Bibian M. E. Tullemans, et al.
Published: (2022-06-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma
by: Filipa Amaro, et al.
Published: (2022-04-01)

Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
by: Kyu Yeon Hur, et al.
Published: (2020-03-01)

Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: A case report
by: Farzaneh Ashrafi, et al.
Published: (2017-01-01)

Sunitinib in mRCC: A systematic review of UK Real World Data
by: David Andrew Montgomery, et al.
Published: (2015-08-01)

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib
by: Satoshi Noda, et al.
Published: (2012-11-01)